Teresa Bitetti’s Post

Difficult for people outside Scandinavia to understand and I guess also for many groups in Scandinavia. 💪 "We have never been Neo-liberals" 😉 DER SPIEGEL: You have made Novo Nordisk Europe's most valuable company, with a greater market capitalization than Daimler, Bayer, Lufthansa and BMW combined. Do you benefit financially? Knudsen: I don’t care that much about money, I’m a socialist! Here in Scandinavia, we teach our children teamwork from an early age. It’s not about the individual. And that’s how I am too. I have never asked for a raise in 34 years. DER SPIEGEL: You never got more money? Not even now? Knudsen: Yes, of course. But I didn’t push. I can’t see that capitalism and money make people happy. At Novo Nordisk, I have always preferred to use my credibility to demand more funding for science, not more salary for myself. I also have no intellectual property rights. They belong to the company because I gave them up when I was employed. https://lnkd.in/dQ9q4hum

As part of our commitment to advancing innovation in cancer treatment, we recently hosted the StarForum event in Mexico, bringing together local hematologists to explore the latest trends in oncology.     The event featured our innovative approaches, including a presentation on the application of AI in hematology and the pharmaceutical industry. The discussion highlighted AI’s role in enhancing drug discovery and development while underscoring the importance of ethical AI use for the benefit of both healthcare professionals and patients.     Watch the event recap here: https://bit.ly/3YJ3UlM #Oncology #ArtificialIntelligence #AI 

We are thrilled that our wholly-owned Japanese subsidiary, #Mirxes Japan, has secured its first Japanese government business grant. Awarded by the Japan External Trade Organization (JETRO), the grant is valued up to 20 million yen (S$172,000) and comes at a pivotal time as Mirxes Japan ramps up product commercialization efforts in Japan. This recognition also underscores Mirxes Japan's dedication and the significant growth it has achieved in the Japanese market. The grant is from JETRO's "Subsidy for Projects to Stimulate Direct Investment in Japan" programme, which aims to assist foreign and foreign-affiliated companies in developing innovative technologies and business models within Japan. For Mirxes, this will support the development and validation of a new non-invasive cancer biomarker screening test specifically designed for Japan. Mirxes Japan's project will involve collaboration with Nagawa Pharmaceutical Co., Ltd and has a budget of 45 million yen. The project aims to introduce Mirxes' RNA technology to Japanese laboratories and increase the number of Japanese patients who can access our tests, which include our flagship stomach cancer early detection test GastroClear, and LungClear. Mirxes is confident that our Asian-focused cancer early detection tests hold immense potential for Japanese cancer patients, and is committed to validating and commercialising them in Japan. JETRO’s announcement: https://lnkd.in/ghVKMyxP #preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetection #earlydetectionsaveslives #healthcare #cancerearlydetection #JETRO #CancerDetection #Healthcare #Japan #BusinessGrant

CRM extends our gratitude to YB Datuk Seri Dr Haji Dzulkefly Ahmad for his time in meeting with Dr Hytham Al-Masri, President and CEO of Hematogenix. CRM aligns with Hematogenix in positioning Malaysia as a hub for clinical research in the region. As a central oncology lab that is strategically located in Cyberjaya, Hematogenix contributes to the country thorough talent development in the industry, creating highly skilled workforce, attracting multi-regional clinical trials in oncology and moving the country's R&D landscape upstream. The socio-economic impact to the country is immeasurable. #clinicalresearchmy #advancingclinicalresearch #askusaboutclinicalresearch

*Pharma IT & Digital Health in Tokyo* Represented at our Finland session: Finnadvance’s organ-on-a-chip technology mimics human biology, a kind of digital twin of human organs for drug development, thus avoiding unethical, slow and costly animal testing. AKITA, by Finnadvance platform is now available for Japanese researchers. Probiont, a top 15 finalist of Arctic 15 last year, makes personalized cancer immunotherapy efficacy testing. A patients cancer is emulated in an organ-on-a-chip and personalized treatment strategies can be tested before applying in real-life. Popit Ltd smart medication tracker supports long term patients with their care. An estimated 50% of patients have challenges remembering their medication, a clear challenge in good healthcare. Monidor Oy smart IV infusion monitoring use case: a hospital unit of 3 day + 3 evening + 2 night shift nurses using Monidor for a month saved 415 routine inspections, avoided 74 problem situations by early detection, among other benefits, totalling 22h more time for care. Thank you Kei Shigaki BF for the nice arrangements! #BusinessFinland #InvestInFinland #Healthtech #Japan

In 2023, Quindio BioTech embarked on a transformative journey, guided by three fundamental principles: 1. Dedication to Rare Diseases ↳ The commitment was unwavering, leaving no room for half-measures. ↳ Their mission: To establish a beacon of hope for rare diseases. 2. Building Stakeholder Engagement ↳ They consistently engaged government entities, pharmaceutical companies, patients, and their families. ↳ Together, they forged a collective effort to reshape healthcare in Quindío. And the most pivotal part... 3. Embracing Positive Outcomes ↳ The new branding warmly received support from universities, scientific institutions, and other key stakeholders. ↳ This branding strategy catalyzed collaboration and yielded tangible positive results. Before dismissing it as mere branding... - Quindío's government fully embraced the initiative. - Leading scientific institutions rallied behind the cause. - Tangible and meaningful outcomes started to materialize. - And this is just the beginning! It's a straightforward formula... Engage → engage more → achieve the extraordinary. Join Quindio BioTech and Jaime Henrique Berrio Trujillo on their journey to revolutionize healthcare in the region! 🏥🤝 P.S. want to see the whole project? https://lnkd.in/eKpnh83E

🚀 Sergio Andrés Torres Pérez's presentation at Biosimilars LatAm - Colombia 2024 shed light on vital collaborations driving #biosimilars development! In the session "Bridging Borders: A Collaborative Journey in Biosimilars Development, INC-Colombia & UDIBI-Mexico", he highlighted UDIBI's collaboration with the Instituto Nacional De Cancerología E.S.E., emphasizing the importance of local manufacturing for biosimilar products. Such partnerships are key to advancing healthcare accessibility and innovation. 💡🤝 #BiosimilarsLatAm #HealthcareInnovation #Collaboration #BiosimilarsDevelopment

🆕 During the month of May, at the #BioRegionCatalonia, outstanding presentations, #investment, #business partnerships and other notable news from the ecosystem have occurred. Let’s review them 👇 🔺 #Biocat presented the new Catalan Health System innovation Access Program (#PASS), a project that will help streamline access to the Catalan Healthcare System for #innovation by identifying, prioritizing and guiding it. 🔺 The investment fund XY Booster Group has chosen #Catalonia for its new innovation hub. Plus, Novartis has inaugurated new offices in #Barcelona, and ESTEVE will expand its factory in Celrà (Girona). 🔺 Loop Diagnostics, a company from the #dHEALTHBcn program, has been granted UKCA marking as an in vitro diagnostic tool for its SeptiLoop device, making it eligible for clinical use in the UK. 🔺 Ysios Capital took part in a €46 million round in NEMO Therapeutics LLC, a company developing antibodies to fight viral diseases. COLUMBUS VENTURE PARTNERS,S.G.E.I.C., S.A.U. closed its 4th fund with €150 million. 🔺 ABLE Human Motion closed an operation for 💰 €875,000, while other startups have also secured #funding. 🔺 GigaGen Inc, a subsidiary of Grifols, kicked off a clinical trial on its first oncology drug to treat metastatic or locally advanced solid tumours. 🔺 OneChain Immunotherapeutics, a #biotech developing CAR-T cell therapies for oncology diseases, began its first clinical trial on OC-1. Read all the news at the wrap up of May: 🗞 https://lnkd.in/d_KjuQ9s

New Report: China Is No Longer a Biotech Imitator; It's Rapidly Catching the West in Innovation @Sandra Barbosu new report from ITIF reveals how China’s biotech sector has transformed from imitator to innovator. Key findings include: 📖 A 382% increase in top-cited research publications in a decade. 🥼 Doubling of clinical trial activity from 2,979 trials in 2017 to 6,497 in 2021. 🎗️ Significant growth in oncology trials, the highest in the world. Since China’s strategic focus on biotech is reshaping the global innovation landscape, the United States must act swiftly to maintain its edge in commercialization, the secret sauce of U.S. leadership. Read the full report to understand the implications for U.S. policy and competitiveness: https://lnkd.in/enF3jhpZ

𝐖𝐞'𝐯𝐞 𝐞𝐱𝐩𝐚𝐧𝐝𝐞𝐝 𝐨𝐮𝐫 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐰𝐢𝐭𝐡 Roche Danmark – 𝐚𝐢𝐦𝐢𝐧𝐠 𝐭𝐨 𝐝𝐫𝐢𝐯𝐞 𝐞𝐯𝐞𝐧 𝐦𝐨𝐫𝐞 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 🚀 🤝 Last week, BETA. HEALTH and Roche shook hands on a shared ambition to pursue more industry-connected corporate partners to join our healthcare innovation efforts. We believe that this path forward will make our impact even greater! Roche has shown us that the industry has unlimited capabilities that can benefit the development, implementation and scaling of innovative clinical solutions – and together, we believe that more BETA. HEALTH-funded projects should benefit from extended partnerships. Our partnership began last summer when we joined forces to create an 'Industry Call' pilot programme aimed at further accelerating clinical innovation. The selected project, cancercare@home, aims to increase care capacity while improving quality of life for cancer patients by enabling them to self-test their blood values at home. The joint programme has connected the cancercare@home team with Roche’s global network of industry experts, who are using their experience and connections to help bring this point-of-care technology to patients. 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 ‘𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐂𝐚𝐥𝐥’ 👉 https://lnkd.in/e3TvnU_i Christian Juul-Nielsen, Rasmus Fält, Agnete Halldorsson, Mikkel Møl Dalsgaard, Bodil Christine Reumert, Sarah Maria Rasch, Rasmus Thomsen, Rasmus Bjørn Dahl